Quartz Partners LLC Raises Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Quartz Partners LLC boosted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,499 shares of the specialty pharmaceutical company’s stock after acquiring an additional 820 shares during the period. Quartz Partners LLC’s holdings in Supernus Pharmaceuticals were worth $1,031,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC increased its position in shares of Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in Supernus Pharmaceuticals during the 3rd quarter valued at about $791,000. Geode Capital Management LLC raised its stake in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after buying an additional 74,438 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock worth $987,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in Supernus Pharmaceuticals in the fourth quarter worth about $1,498,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $33.05 on Monday. The company has a market cap of $1.82 billion, a price-to-earnings ratio of 30.89 and a beta of 0.90. The stock’s fifty day moving average price is $37.48 and its 200 day moving average price is $35.38. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $57.00 to $36.00 in a report on Wednesday, February 19th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.